Loading
Terremoto Biosciences makes tablets that block AKT1, a growth signal that is switched on in many breast and other cancers, while trying to avoid the side effects of blocking related proteins. Its lead drug, TER-2013, is in an early trial.
Terremoto Biosciences Inc., based in South San Francisco and San Diego, California, designs small molecules using lysine-targeted covalent chemistry. Its lead oncology programme TER-2013 is an AKT1-selective inhibitor for solid tumours with alterations in PIK3CA, AKT or PTEN; in May 2026 the company announced FDA Fast Track designation for TER-2013 in HR-positive, HER2-negative breast cancer with these alterations after endocrine and CDK4/6 inhibitor therapy. A second programme, TER-4480, targets hereditary haemorrhagic telangiectasia. In April 2026 it closed a USD 108 million Series C with new investors RA Capital Management, Deep Track Capital, Osage University Partners and BeOne Medicines and existing investors OrbiMed, Third Rock Ventures, Novo Holdings and Cormorant. Its first registered cancer trial, NCT07109726, a phase 1/2 study of TER-2013 alone and with fulvestrant in solid tumours harbouring AKT, PI3K or PTEN pathway alterations, including breast, endometrial, ovarian, cervical and squamous cancers of the lung, head and neck and oesophagus, was posted on ClinicalTrials.gov in August 2025.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series C · New investors RA Capital Management, Deep Track Capital, Osage University Partners and BeOne Medicines, with OrbiMed, Third Rock Ventures, Novo Holdings and Cormorant | 2026 | $108M | terremotobio.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Third Rock Ventures, Cormorant Asset Management, PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha.
Shares OrbiMed, AKT, PI3K, AKT and mTOR inhibitors, Endometrial cancer.
Shares PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha, Endometrial cancer, Head and neck squamous cell carcinoma.
Shares Novo Holdings, OrbiMed, RA Capital Management.
Shares PTEN, AKT, PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha.
Shares PTEN, AKT, PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha.
Shares Third Rock Ventures, RA Capital Management.
Shares PTEN, AKT, PI3K, AKT and mTOR inhibitors, PIK3CA / PI3K-alpha.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/